Abstract:Multivalent drugs targeting homo-oligomeric viral surface proteins, such as the SARS-CoV-2 trimeric spike (S) protein, have the potential to elicit more potent and broad-spectrum therapeutic responses than monovalent drugs by synergistically engaging multiple binding sites on viral targets. However, rational design and engineering of nanoscale multivalent protein drugs are still lacking. Here, we developed a computational approach to engineer self-assembling trivalent microproteins that simultaneously bind to the three receptor binding domains (RBDs) of the S protein. This approach involves four steps: structure-guided linker design, molecular simulation evaluation of self-assembly, experimental validation of self-assembly state, and functional testing. Using this approach, we first designed trivalent constructs of the microprotein miniACE2 (MP) with different trimerization scaffolds and linkers, and found that one of the constructs (MP-5ff) showed high trimerization efficiency, good conformational homogeneity, and strong antiviral neutralizing activity. With its trimerization unit (5ff), we then engineered a trivalent nanobody (Tr67) that exhibited potent and broad neutralizing activity against the dominant Omicron variants, including XBB.1 and XBB.1.5. Cryo-EM complex structure confirmed that Tr67 stably binds to all three RBDs of the Omicron S protein in a synergistic form, locking them in the “3-RBD-up” conformation that could block human receptor (ACE2) binding and potentially facilitate immune clearance. Therefore, our approach provides an effective strategy for engineering potent protein drugs against SARS-CoV-2 and other deadly coronaviruses.

Heteromultivalent Topology-Matched Nanostructures As Potent and Broad-Spectrum Influenza A Virus Inhibitors.

Topology‐Matching Design of an Influenza‐Neutralizing Spiky Nanoparticle‐Based Inhibitor with a Dual Mode of Action

Spiky Nanostructures with Geometry-matching Topography for Virus Inhibition

Spatially Patterned Neutralizing Icosahedral DNA Nanocage for Efficient SARS-CoV-2 Blocking

Spiky Nanostructures for Virus Inhibition and Infection Prevention

Novel mono- and multivalent N -acetylneuraminic acid glycoclusters as potential broad-spectrum entry inhibitors for influenza and coronavirus infection

Rational Development of Hypervalent Glycan Shield-Binding Nanoparticles with Broad-Spectrum Inhibition against Fatal Viruses Including SARS-CoV-2 Variants

Antiviral Drug Design Based on Structural Insights into the N-terminal Domain and C-terminal Domain of the SARS-CoV-2 Nucleocapsid Protein

Antigen Spatial-Matching Polyaptamer Nanostructure to Block Coronavirus Infection and Alleviate Inflammation

Pentacyclic triterpenes grafted on CD cores to interfere with influenza virus entry: A dramatic multivalent effect.

Covalent Organic Framework-Based Theranostic Platforms for Restricting H1N1 Influenza Virus Infection

Computational Design and Engineering of Self-Assembling Multivalent Microproteins with Therapeutic Potential Against SARS-CoV-2

Design, Synthesis and Biological Evaluation of "Multi-Site"-binding Influenza Virus Neuraminidase Inhibitors.

Targeted Agglutination of Corona Virus by Tapered Chiral Nanoparticles

A Combined NMR-Computational Study of the Interaction between Influenza Virus Hemagglutinin and Sialic Derivatives from Human and Avian Receptors on the Surface of Transfected Cells

Residue-based Design of Small Molecule Inhibitor for H1N1, H5N1 and H7N1 Mutants

Design, Synthesis And Biological Activity Evaluation Of Novel Conjugated Sialic Acid And Pentacyclic Triterpene Derivatives As Anti-Influenza Entry Inhibitors

Multivalent Neuraminidase Hydrolysis Resistant Triazole-Sialoside Protein Conjugates As Influenza-Adsorbents

Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity

Polyvalent Nanobody Structure Designed for Boosting SARS-CoV-2 Inhibition

Glycopolymer with Sulfated Fucose and 6'-Sialyllactose as a Dual-Targeted Inhibitor on Resistant Influenza A Virus Strains